{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:20:15Z","timestamp":1774984815746,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI grant","award":["(C) 16K08487"],"award-info":[{"award-number":["(C) 16K08487"]}]},{"name":"JSPS KAKENHI grant","award":["(C) 22K11849"],"award-info":[{"award-number":["(C) 22K11849"]}]},{"name":"Collaborative research fund from Nippon Chemiphar Co., Ldt."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The beneficial effects of oral supplements with alkalinizing agents in patients with chronic kidney disease (CKD) have been limited to the severe stages. We investigated whether two types of supplements, sodium bicarbonate (SB) and potassium citrate\/sodium citrate (PCSC), could maintain renal function in patients with mild-stage CKD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a single-center, open-labeled, randomized cohort trial. Study participants with CKD stages G2, G3a, and G3b were enrolled between March 2013 and January 2019 and randomly assigned by stratification according to age, sex, estimated glomerular filtration rate (eGFR), and diabetes. They were followed up for 6\u00a0months (short-term study) for the primary endpoints and extended to 2\u00a0years (long-term study) for the secondary endpoints. Supplementary doses were adjusted to achieve an early morning urinary pH of 6.8\u20137.2. We observed renal dysfunction or new-onset cerebrovascular disease and evaluated urinary surrogate markers for renal injury.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 101 participants were registered and allocated to three groups: standard (<jats:italic>n<\/jats:italic>\u2009=\u200932), SB (<jats:italic>n<\/jats:italic>\u2009=\u200934), and PCSC (<jats:italic>n<\/jats:italic>\u2009=\u200935). Two patients in the standard group attained the primary endpoints (renal stones and overt proteinuria) but were not statistically significant. There was one patient in the standard reduced eGFR during the long-term study (<jats:italic>p<\/jats:italic>\u2009=\u20090.042 by ANOVA). SB increased proteinuria (<jats:italic>p<\/jats:italic>\u2009=\u20090.0139, baseline vs. 6\u00a0months), whereas PCSC significantly reduced proteinuria (<jats:italic>p<\/jats:italic>\u2009=\u20090.0061, baseline vs. 1\u00a0year, or <jats:italic>p<\/jats:italic>\u2009=\u20090.0186, vs. 2\u00a0years) and urinary excretion of 8-hydroxy-2\u2032-deoxyguanosine (<jats:italic>p<\/jats:italic>\u2009=\u20090.0481, baseline vs. 6\u00a0months).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study is the first to report supplementation of PCSC reduced intrarenal oxidative stress in patients with mild-stage CKD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s10157-024-02517-3","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T13:01:27Z","timestamp":1718283687000},"page":"1134-1154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oral alkalinizing supplementation suppressed intrarenal reactive oxidative stress in mild-stage chronic kidney disease: a randomized cohort study"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0633-8462","authenticated-orcid":false,"given":"Michiaki","family":"Abe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seizo","family":"Koshiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Umeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Masaura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Arita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Akaishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"CKOALA study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"2517_CR1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1159\/000516371","volume":"7","author":"M Adamczak","year":"2021","unstructured":"Adamczak M, Surma S. Metabolic acidosis in patients with CKD: epidemiology, pathogenesis, and treatment. Kidney Dis. 2021;7:452\u201367.","journal-title":"Kidney Dis"},{"key":"2517_CR2","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.2215\/CJN.07400715","volume":"10","author":"LL Hamm","year":"2015","unstructured":"Hamm LL, Nakhoul N, Hering-Smith KS. Acid-b homeostasis. Clin J Am Soc Nephrol. 2015;10:2232\u201342.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2517_CR3","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1681\/ASN.2008111205","volume":"20","author":"I de Brito-Ashurst","year":"2009","unstructured":"de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20:2075\u201384.","journal-title":"J Am Soc Nephrol"},{"key":"2517_CR4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40620-019-00656-5","volume":"32","author":"BR Di Iorio","year":"2019","unstructured":"Di Iorio BR, Bellasi A, Raphael KL, et al. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. J Nephrol. 2019;32:989\u20131001.","journal-title":"J Nephrol"},{"key":"2517_CR5","first-page":"121","volume":"35","author":"AK Dubey","year":"2020","unstructured":"Dubey AK, Sahoo J, Vairappan B, et al. Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial. Nephrol Dial Transplant. 2020;35:121\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"2517_CR6","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/ki.2014.83","volume":"86","author":"N Goraya","year":"2014","unstructured":"Goraya N, Simoni J, Jo CH, Wesson DE. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int. 2014;86:1031\u20138.","journal-title":"Kidney Int"},{"key":"2517_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000500042","volume":"49","author":"N Goraya","year":"2019","unstructured":"Goraya N, Munoz-Maldonado Y, Simoni J, et al. Fruit and vegetable treatment of chronic kidney disease-related metabolic acidosis reduces cardiovascular risk better than sodium bicarbonate. Am J Nephrol. 2019;49:438\u201348.","journal-title":"Am J Nephrol"},{"key":"2517_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/ki.2010.129","volume":"78","author":"A Mahajan","year":"2010","unstructured":"Mahajan A, Simoni J, Sheather SJ, et al. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int. 2010;78:303\u20139.","journal-title":"Kidney Int"},{"key":"2517_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12916-020-01542-9","volume":"18","author":"BiCARB study group","year":"2020","unstructured":"BiCARB study group. Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial. BMC Med. 2020;18:91.","journal-title":"BMC Med"},{"key":"2517_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1681\/ASN.2019030287","volume":"31","author":"KL Raphael","year":"2020","unstructured":"Raphael KL, Isakova T, Ix JH, et al. A randomized trial comparing the safety, adherence, and pharmacodynamics profiles of two doses of sodium bicarbonate in CKD: the BASE pilot trial. J Am Soc Nephrol. 2020;31:161\u201374.","journal-title":"J Am Soc Nephrol"},{"key":"2517_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.ajkd.2019.07.016","volume":"75","author":"ML Melamed","year":"2020","unstructured":"Melamed ML, Horwitz EJ, Dobre MA, et al. Effects of sodium bicarbonate in CKD stages 3 and 4: a randomized, placebo-controlled, multicenter clinical trial. Am J Kidney Dis. 2020;75:225\u201334.","journal-title":"Am J Kidney Dis"},{"key":"2517_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ki.2009.519","volume":"77","author":"S Phisitkul","year":"2010","unstructured":"Phisitkul S, Khanna A, Simoni J, et al. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int. 2010;77:617\u201323.","journal-title":"Kidney Int"},{"key":"2517_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12882-020-01807-8","volume":"21","author":"M Abe","year":"2020","unstructured":"Abe M, Akaishi T, Shoji M, CKOALA study group, et al. Reno-protective effects of oral alkalizing agents in chronic kidney disease with aciduria: protocol for a randomized cohort study. BMC Nephrol. 2020;21:144.","journal-title":"BMC Nephrol"},{"key":"2517_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1053\/j.ackd.2022.02.011","volume":"29","author":"N Goraya","year":"2022","unstructured":"Goraya N, Narayanan M, Wesson DE. Management of metabolic acidosis in chronic kidney disease: past, present, and future direction. Adv Chronic Kidney Dis. 2022;29:416\u201323.","journal-title":"Adv Chronic Kidney Dis"},{"key":"2517_CR15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Collaborators developing the Japanese equation for estimated GFR, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2517_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1681\/ASN.2009111130","volume":"22","author":"T Souma","year":"2011","unstructured":"Souma T, Abe M, Moriguchi T, et al. Luminal alkalinization attenuates proteinuria-induced oxidative damage in proximal tubular cells. J Am Soc Nephrol. 2011;22:635\u201348.","journal-title":"J Am Soc Nephrol"},{"key":"2517_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5049\/EBP.2021.19.2.29","volume":"19","author":"HJ Kim","year":"2021","unstructured":"Kim HJ. Metabolic acidosis in chronic kidney disease: pathogenesis, clinical consequences, and treatment. Electrolyte Blood Press. 2021;19:29\u201337.","journal-title":"Electrolyte Blood Press"},{"key":"2517_CR18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2147\/TCRM.S344592","volume":"17","author":"F Cheng","year":"2021","unstructured":"Cheng F, Li Q, Wang J, et al. The effects of oral sodium bicarbonate on renal function and cardiovascular risk in patients with chronic kidney disease: a systematic review and meta-analysis. Ther Clin Risk Manag. 2021;17:1321\u201331.","journal-title":"Ther Clin Risk Manag"},{"key":"2517_CR19","doi-asserted-by":"publisher","first-page":"F350","DOI":"10.1152\/ajprenal.00407.2005","volume":"291","author":"M Abe","year":"2006","unstructured":"Abe M, Kaldunski M, Liang M, et al. Effect of sodium delivery on superoxide and nitric oxide in the medullary thick ascending limb. Am J Physiol Renal Physiol. 2006;291:F350\u20137.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2517_CR20","doi-asserted-by":"publisher","first-page":"F179","DOI":"10.1152\/ajprenal.00455.2014","volume":"308","author":"AW Cowley Jr","year":"2015","unstructured":"Cowley AW Jr, Abe M, Mori T, et al. Reactive oxygen species as important determinants of medullary flow, sodium excretion and hypertension. Am J Physiol Renal Physiol. 2015;308:F179\u201397.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2517_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1667\/RR1454.1","volume":"171","author":"M Lenarczyk","year":"2009","unstructured":"Lenarczyk M, Cohen EP, Fish BL, et al. Chronic oxidative stress as a mechanism for radiation nephropathy. Radiat Res. 2009;171:164\u201372.","journal-title":"Radiat Res"},{"key":"2517_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1089\/jmf.2021.K.0138","volume":"25","author":"JR Na","year":"2022","unstructured":"Na JR, Kim E, Na CS, Kim S. Citric acid-enriched extract of ripe Prunus mume (Siebold) Siebold & Zucc induces laxative effects by regulating the expression of aquaporin 3 and prostaglandin E(2) in rats with loperamide-induced constipation. J Med Food. 2022;25:12\u201323.","journal-title":"J Med Food"},{"key":"2517_CR23","doi-asserted-by":"publisher","first-page":"1058464","DOI":"10.3389\/fmed.2022.1058464","volume":"9","author":"WH Zheng","year":"2023","unstructured":"Zheng WH, Zhu YB, Yao Y, Huang HB. Serum creatinine\/cystatin C ratio as a muscle mass evaluating tool and prognostic indicator for hospitalized patients: a meta-analysis. Front Med (Lausanne). 2023;9:1058464.","journal-title":"Front Med (Lausanne)"},{"key":"2517_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12970-019-0297-4","volume":"16","author":"VCR Cunha","year":"2019","unstructured":"Cunha VCR, Aoki MS, Zourdos MC, et al. Sodium citrate supplementation enhances tennis skill performance: a crossover, placebo-controlled, double-blind study. J Int Soc Sports Nutr. 2019;16:32.","journal-title":"J Int Soc Sports Nutr"},{"key":"2517_CR25","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1046\/j.1523-1755.2002.00656.x","volume":"62","author":"S Domrongkitchaiporn","year":"2002","unstructured":"Domrongkitchaiporn S, Pongskul C, Sirikulchayanonta V, et al. Bone histology and bone mineral density after correction of acidosis in distal renal tubular acidosis. Kidney Int. 2002;62:2160\u20136.","journal-title":"Kidney Int"}],"updated-by":[{"DOI":"10.1007\/s10157-025-02733-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000}}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02517-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-024-02517-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-024-02517-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T20:15:30Z","timestamp":1757103330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-024-02517-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2517"],"URL":"https:\/\/doi.org\/10.1007\/s10157-024-02517-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10157-025-02733-5","asserted-by":"object"}]},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]},"assertion":[{"value":"31 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the units of UAE in table 2 and 4.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10157-025-02733-5","URL":"https:\/\/doi.org\/10.1007\/s10157-025-02733-5","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nippon Chemiphar Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All the study procedures were approved by the Institutional Review Board of Tohoku University Hospital (IRB2012-2\u2013100-1, CRB2200003) and were performed in compliance with the Declaration of Helsinki of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}